Ambu A/S banner

Ambu A/S
CSE:AMBU B

Watchlist Manager
Ambu A/S Logo
Ambu A/S
CSE:AMBU B
Watchlist
Price: 67.55 DKK -0.73%
Market Cap: kr15.9B

Ambu A/S
Total Liabilities & Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Ambu A/S
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Ambu A/S
CSE:AMBU B
Total Liabilities & Equity
kr7.6B
CAGR 3-Years
3%
CAGR 5-Years
8%
CAGR 10-Years
N/A
GN Store Nord A/S
CSE:GN
Total Liabilities & Equity
kr29.2B
CAGR 3-Years
-2%
CAGR 5-Years
12%
CAGR 10-Years
10%
Demant A/S
CSE:DEMANT
Total Liabilities & Equity
kr39.1B
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
11%
V
ViroGates A/S
CSE:VIRO
Total Liabilities & Equity
kr14.2m
CAGR 3-Years
-11%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
No Stocks Found

Ambu A/S
Glance View

Market Cap
15.9B DKK
Industry
Health Care

Ambu A/S, a Danish company rooted in innovation, has carved a niche in the global healthcare sector through its specialized medical devices. Founded in 1937, Ambu started with a simple mission of improving patient care and has stayed true to that vision by continuously advancing their portfolio. The company's journey began with the invention of the resuscitator bag, a revolutionary product that remains a staple in emergency and hospital settings today. Over the years, Ambu has focused strategically on three main segments: Anesthesia, Patient Monitoring & Diagnostics, and Visualisation, each playing a crucial role in the broader healthcare ecosystem. These segments allow Ambu to develop devices that enhance diagnostic procedures, improve safety, and increase efficiency in medical settings, ultimately saving lives and optimizing healthcare delivery. Ambu’s business model capitalizes primarily on innovation-driven sales, with a strong emphasis on disposable medical devices which are gaining popularity due to hygiene concerns and regulatory trends favoring single-use technologies. These products include their flagship single-use endoscopes, marketed under the brand name "Ambu aScope," which significantly reduce the risk of cross-contamination while providing high-quality diagnostic images. The company's revenue model is built on a B2B approach, dealing directly with hospitals, clinics, and other healthcare providers, ensuring a steady flow of sales through long-term contracts and partnerships. Through constant reinvestment into R&D and strategic acquisitions, Ambu sustains its market leadership, driving growth by addressing the evolving needs of the healthcare industry and setting standards in patient care solutions globally.

AMBU B Intrinsic Value
108.82 DKK
Undervaluation 38%
Intrinsic Value
Price kr67.55

See Also

What is Ambu A/S's Total Liabilities & Equity?
Total Liabilities & Equity
7.6B DKK

Based on the financial report for Dec 31, 2025, Ambu A/S's Total Liabilities & Equity amounts to 7.6B DKK.

What is Ambu A/S's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
8%

Over the last year, the Total Liabilities & Equity growth was 6%. The average annual Total Liabilities & Equity growth rates for Ambu A/S have been 3% over the past three years , 8% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett